Lasmiditan succinate

Lasmiditan succinate is a pharmaceutical drug used in the treatment of migraine. It is a selective serotonin receptor agonist, specifically targeting the 5-HT1F receptor.

Pharmacology

Lasmiditan succinate works by selectively targeting the 5-HT1F receptor, a subtype of the serotonin receptor. This receptor is found in high concentrations in the trigeminal nerve, which is involved in the pathophysiology of migraine. By activating this receptor, lasmiditan succinate can inhibit the release of inflammatory mediators and decrease the transmission of pain signals, thereby relieving the symptoms of a migraine.

Clinical Use

Lasmiditan succinate is indicated for the acute treatment of migraine with or without aura in adults. It is available in oral tablet form and is typically used when other first-line treatments for migraine, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or triptans, are ineffective or contraindicated.

Side Effects

Common side effects of lasmiditan succinate include dizziness, fatigue, paresthesia, and sedation. As with all medications, it should be used with caution in patients with a history of cardiovascular disease or liver disease, as it may exacerbate these conditions.

Development and Approval

Lasmiditan succinate was developed by Eli Lilly and Company, and received approval from the Food and Drug Administration (FDA) in October 2019. It is marketed under the brand name Reyvow.

See Also

• Serotonin receptor agonist
• Migraine
• 5-HT1F receptor
• Eli Lilly and Company